



ASX ANNOUNCEMENT

29 November 2016

Cynata Files Further Patent Application

Melbourne, Australia; 29 November 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has filed a further patent application describing certain novel aspects of the Company's proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) technology.

This new patent application, which is owned by Cynata, adds to the Company's growing intellectual property portfolio, and further strengthens Cynata's position as a leader in the economical production of single donor-derived, clinical grade MSCs. Should the application mature to a granted patent, it will provide valuable commercial exclusivity in key markets around the world. The new discovery described in the patent application builds on the Cymerus technology and provides additional protection for the Company's unique MSC assets.

"Cynata continues to identify novel and commercially important aspects of its Cymerus technology and, consistent with our goal to continue expanding our substantial and defensible intellectual property estate, this new filing is an important achievement for our business model and for the wider stem cell therapeutics industry", said Dr Ross Macdonald, Cynata's Managing Director and Chief Executive Officer.

The Company also advises that good progress has been made in completing the definitive agreements in respect of the proposed product development and commercialisation transaction with Fujifilm.

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Rudi Michelson, Monsoon, Australia Media Contact, 0411 402 737, rudim@monsoon.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited
Suite 1, 1233 High Street, Armadale, Victoria 3143, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
ABN - 98 104 037 372